Aurora Cannabis Reports Q3 Fiscal 2025 Results

TL;DR

ACB dropped Q3 FY25 results Feb 5; CEO Miguel Martin signed off.

AI Summary

Aurora Cannabis Inc. announced its fiscal 2025 third quarter results on February 5, 2025. The company filed a Form 6-K report with the SEC, which included a news release detailing these results. Miguel Martin, the Chief Executive Officer, signed the report.

Why It Matters

This filing provides investors with the latest financial performance data for Aurora Cannabis, crucial for understanding the company's current operational health and future prospects in the cannabis market.

Risk Assessment

Risk Level: medium — Aurora Cannabis operates in a highly regulated and competitive industry, which presents inherent risks to its financial performance and stock valuation.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Filer of the report
• Miguel Martin (person) — Chief Executive Officer and signatory of the report
• February 5, 2025 (date) — Date of the news release and filing
• NASDAQ | TSX: ACB (company) — Stock ticker symbols for Aurora Cannabis

FAQ

From the Filing

0001279569-25-000102.txt : 20250205 0001279569-25-000102.hdr.sgml : 20250205 20250205072009 ACCESSION NUMBER: 0001279569-25-000102 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250205 FILED AS OF DATE: 20250205 DATE AS OF CHANGE: 20250205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 25590890 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated February 5, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: February 5, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 5, 2025 Exhibit 99.1 Aurora Cannabis Announces Fiscal 2025 Third Quarter Results NASDAQ | TSX: ACB Reports Total Net Revenue 1 of $88.2 Million, up 37% YoY, Including Record Net Revenue 1 of $68.1 Million in Global Medical Cannabis, up 51% YoY Generates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA 1 of $23.1 Million, up 316% YoY Achieves Target of Positive Free Cash Flow 1 in Q3, Generating $27.4 Million of Free Cash Flow 1 Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business 2 EDMONTON, AB, Feb. 5, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter fiscal 2025. "This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue 1 , net income, adjusted EBITDA 1 , and free cash flow 1 . These achievements, along with our strong cash position and debt-free cannabis business, underscore Aurora's leadership in the global cannabis industry as we continue to set ourselves apart from our peers," said Miguel Martin, Executive Chairman and Chief Executive Officer for Aurora Cannabis. "Our strong top-line performance and record adjusted EBITDA 1 were mostly fueled by contributions from our global medical cannabis business. International net revenue 1 grew 112% and accounted for 60% of global medical cannabis net revenue 1 . Additionally, our plant propagation segment increased 22%, driven by organic expansion and an enhanced product portfolio, further strengthening our operating model. Our stated goals of continued strategic growth, operational excellence, and long-term sustained profitability are unwavering and we are deeply appreciative of our team's efforts in helping us achieve these milestones," concluded Mr. Martin. _________________________________________________________________________________________ 1 This press release includes certain non-GAAP financial meas